- Institutions (830)
- Other institutions (46)
Adlbrecht, C. and Breyer, E. and Gartlehner, G. and Guba, B. (2008): Selective Cell Apheresis in Inflammatory Bowel Disease. Decision Support Document 11.
Arrich, J. and Piribauer, F. and Mad, P. and Schmid, D. (2005): Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: Systematic review and meta-analysis. CMAJ: Canadian Medical Association Journal 172 (8): 1039-1043.
Breuer, J. and Joppi, R. and Poggiani, C. and Dabrowska, M. and Zawodnik, A. and Nachtnebel, A. (2014): Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 45.
Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.
Breyer, E. (2008): [Templates for reimbursement applications]. Masters.
Erdos, J. and Mayer, J. (2015): Sphenopalatine Ganglion (SPG) stimulation of patients with therapy-resistant cluster headache. Decision Support Document 86.
Ettinger, S. and Stanak, M. and Huić, M. and Hacek, R.T. and Ercevic, D. and Grenkovic, R. and Wild, C. (2016): Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk. Decision Support Document 103.
Fischer, S. and Zechmeister-Koss, I. (2015): Intrastromal corneal implants for ectatic corneal disorders. Decision Support Document 85.
Fried, A. and Wild, C. (2013): Hybrid operating room. Rapid Assessment 006.
Jeitler, K. and Semlitsch , T. (2012): Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. DSD: Horizon Scanning in Oncology 32.
Jeitler, K. and Semlitsch, T. (2012): Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer. DSD: Horizon Scanning in Oncology 27.
Joppi, R and Nachtnebel, A. (2012): Trametinib for advanced or metastatic BRAF V600 mutation-positive melanoma. DSD: Horizon Scanning in Oncology 34.
Joppi, R. and Nachtnebel, A. (2012): Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma . DSD: Horizon Scanning in Oncology 30.
Kisser, A. and Kirisits, A. (2015): Endovascular embolization of unruptured intracranial aneurysms with flow diverters. Decision Support Document 83.
Mad, P. and Domanovits, H. and Fazelnia, C. and Stiassny, K. (2007): Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction. QJM: An International Journal of Medicine 100 (4): 203-210.
McGahan, Lynda (2016): Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma. DSD: Horizon Scanning in Oncology 61.
Nachtnebel, A. and Maran , P.R. and Alberti, C. and Garbaty , T. and Czeczot , J. (2012): Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion. DSD: Horizon Scanning in Oncology 28.
Nachtnebel, A. and Polkowska, M. and Czeczot , J. and Joppi, R. and Poggiani, C. (2013): Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer . DSD: Horizon Scanning in Oncology 36.
Nachtnebel, A. and Reinsperger, I. (2012): Percutaneous repair of mitral regurgitation with the MitraClip® . Decision Support Document 41 / Update 2012.
Nachtnebel, A. and Ujeyl, M. (2015): Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer. DSD: Horizon Scanning in Oncology 53.
Naimer, Ch. and Piso, B. (2015): Outpatient neurological rehabilitation: goal attainment in stroke patients. Systematic review. Decision Support Document 92.
Piso, B. and Tüchler, H. (2016): Outpatient cardiac rehabilitation part VI: prospective multi-centre cohort study (comparing patients with and without phase III). HTA-Projektbericht 90.
Poggiani, C. and Hintringer, K. (2012): Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC) . DSD: Horizon Scanning in Oncology 21.
Poggiani, C. and Nachtnebel, A. (2012): Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma. DSD: Horizon Scanning in Oncology 33.
Reinsperger, I. and Piso, B. (2015): Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation (2nd Update 2015). Decision Support Document 44/ 2. Update 2015.
Reinsperger, I. and Piso, B. (2015): Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB) (1st Update 2015). Decision Support Document 68/ 1. Update 2015.
Rothschedl, E. and Joppi, R. and Poggiani, C. (2014): Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 49.
Rothschedl, E. and Nachtnebel, A. (2015): Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease. Decision Support Document 84.
Salamon, Maria (2016): Screening, diagnostics and indication for occupational therapy in children and adolescents with Developmental Coordination Disorders. Decision Support Document 96.
Sassi, F. and McDaid, D. (1998): Transnational analysis of the socio-economic impact of Alzheimer's disease (AD) in the European Union. Report to DG V of the European Commission.
Semlitsch , T. and Jeitler, K. (2013): Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) . DSD: Horizon Scanning in Oncology 35.
Semlitsch, T. and Horvath, K. (2016): Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB). 2nd Update 2016 . Decision Support Document 24/ 2. Update 2016.
Semlitsch, T. and Zengerer, A. and Jeitler, K. (2014): Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas. DSD: Horizon Scanning in Oncology 43.
Semlitsch, T. and Zengerer, A. and Jeitler, K. (2013): Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma. DSD: Horizon Scanning in Oncology 42.
Ujeyl, M. and Nachtnebel, A. (2015): Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma. DSD: Horizon Scanning in Oncology 50.
Wild, C. (1996): [Medical technology assessment: The social implications of the increasing spread of technology in health care]. In: Tichy, G. Technikfolgenabschätzung in Österreich: Wien: Verlag der Österreichischen Akademie der Wissenschaften.
Wild, C. and Gregor-Patera, N. (2015): HTA-Strategy for Lithuania. Decision Support Document 90a.
Wild, C. and Gregor-Patera, N. and Stricka, M. and Karnickas, L. (2015): Background Analysis for National HTA Strategy for Lithuania: Focus on Medical Devices. Decision Support Document 90.
Wild, C. and Peissl, W. (1996): [Patient cards: An assessment of a new information technology in health care]. In: Tichy, G. Technikfolgenabschätzung in Österreich – Entscheidungshilfe in einer komplexen Welt, Beispiele aus der Praxis: Wien: Verlag der Österreichischen Akademie der Wissenschaften.
Winkler, R. (2015): Transcatheter mitral valve-in-valve implantation. Decision Support Document 82.
Winkler, R. (2015): Injectable bulking agents for faecal incontinence. Decision Support Document 87.
Zechmeister, I. and Österle, A. (2006): Distributional impacts of mental health care financing arrangements: A comparison of the UK, Germany and Austria. Journal of Mental Health Policy and Economics 9 (1): 34-44.
Zechmeister, I. and Stollenwerk, B. and Ara, R. and Ward, S. (2008): Statins for the Secondary Prevention of Cardiovascular Diseases: An Analysis of Expected Population Health Gains and Cost-Utility in Austria (Part II of the project 'Statins: A comparison between predicted and actual effects on population health in Austria') . HTA-Projektbericht 018.
Zechmeister, I. and Stollenwerk, B. and Langley, T. (2008): Have Statins Met Our Expectations? A Comparison of Expected Health Gains from Statins with Epidemiological Trends in Austria (Part III of the Project 'Statins: A Comparison Between Predicted and Actual Effects on Population Health in Austria'). HTA-Projektbericht 019.
Zechmeister-Koss, I. (2013): Zostavax® for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA Core Model for Rapid Relative Effectiveness Assessment. Pilot-ID: WP-SA-1. Decision Support Document 73.
Zechmeister-Koss, I. and Rothschedl, E. (2015): Fully bioresorbable scaffolds for coronary artery disease. Decision Support Document 81.